The miracle of science. Preschool and day care weren’t common, so there was less exposure. Parents sent children to play with ...
2don MSN
Study reveals genetic link between childhood brain disorder and Parkinson's disease in adults
Errors in a gene known to cause a serious neurodevelopmental condition in infants are also linked to the development of ...
The causes of heart disease are varied and often interlinked. Hypertension remains the biggest driver, silently damaging the ...
No one should have to suffer from the dry, flaky skin and blisters that are the most common symptoms of eczema, researchers at the Johns Hopkins School of Medicine want Marylanders to know. “Eczema is ...
Scientists have discovered that mutations in the EPG5 gene—known for causing the rare childhood disorder Vici syndrome—also increase the risk of Parkinson’s disease and dementia later in life.
Italy won plaudits for its discipline and unity in fighting the Western world's first coronavirus outbreak in the spring, but that sense of common purpose is unravelling in the face of the second wave ...
Kawasaki disease is most likely to affect children under five years old and of Asian heritage. Here's how to recognize the ...
The Department of Veterans Affairs spends billions on dubious and even fraudulent disabilities benefits. Meanwhile, some ...
Americans are iron deficient and at risk of anemia. You can combat iron deficiency with iron supplements and diet.
2don MSN
Heavy menstrual bleeding: A condition more common than asthma or diabetes, yet often ignored
Every minute, a woman in the U.S. requires a blood transfusion due to heavy menstrual bleeding, or HMB. One in three women reports having the condition—which can lead to iron deficiency and anemia—and ...
Introduction The suicide risk among discharged psychiatric patients is substantially higher than that among patients with physical diseases and the general population. In China, few cohort studies ...
Vietnam Investment Review on MSN
FDA Lifts Clinical Hold on NUZ-001
Highlights: U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS Clears the way for entry into the HEALEY ALS Platform Trial expected to commence in Q4 CY2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results